Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy in Patients with cN0, T1 or T2 Invasive Breast Cancer By Ogkologos - January 14, 2025 977 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the INSEMA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Saying YES: Inspiring a Diverse Generation of Cancer Scientists October 8, 2020 ASCO20 Virtual Research Round Up Podcast: Head and Neck Cancer and... August 13, 2020 Tumors With KRAS G12C Mutation Respond to Adagrasib and Using Toripalimab... April 19, 2023 EMA Recommends Granting a Marketing Authorisation for Datopotamab Deruxtecan February 20, 2025 Load more HOT NEWS Hiding in plain sight: How we can use immune cells to... ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of... Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or...
